Effectiveness of iguratimod as monotherapy or combined therapy in patients with rheumatoid arthritis: a systematic review and meta-analysis of RCTs

Hu, Chao-Jun; Zhang, Li; Zhou, Shuang; Jiang, Nan; Zhao, Jiu-Liang; Wang, Qian; Tian, Xin-Ping; Zeng, Xiao-Feng

doi:10.1186/s13018-021-02603-2

Journal of Orthopaedic Surgery and Research

Table 1 Characteristics of included studies

From: Effectiveness of iguratimod as monotherapy or combined therapy in patients with rheumatoid arthritis: a systematic review and meta-analysis of RCTs

Study	Participants, n	RA type	Intervention	Duration	Outcomes
Xia 2016	150	Active RA	IGU+MTX vs. IGU vs. MTX	24 weeks	ACR20, ACR50, ACR70, DAS28-ESR, DAS28-CRP, duration of morning stiffness, HAQ, adverse events.
Zhao 2017	96	Active RA	IGU+MTX vs. IGU vs. MTX	24 weeks	ACR20, ACR50, ACR70, DAS28-CRP, HAQ, adverse events.
Cao 2018	90	Active RA	IGU+MTX vs. IGU vs. MTX	24 weeks	DAS28-CRP, HAQ
Xu 2015	110	Active RA	IGU+MTX vs. IGU vs. MTX	52 weeks	Duration of morning stiffness, adverse events.
Zhao 2016	90	Active RA	IGU+MTX vs. IGU vs. MTX	24 weeks	ACR20, ACR50, ACR70, adverse events.
Xiong 2015	86	Active RA	IGU+MTX vs.IGU vs. MTX	24 weeks	DAS28-ESR, adverse events.
Lv 2014	131	Active RA	IGU+MTX vs. IGU vs. MTX	24 weeks	DAS28-ESR, DAS28-CRP, duration of morning stiffness, HAQ
Duan 2015	60	Active RA	IGU+MTX vs. MTX	24 weeks	ACR20, ACR50, ACR70, DAS28, HAQ, adverse events.
Ishiguro 2013	252	Active RA	IGU+MTX vs. MTX	24 weeks	ACR20, ACR50, ACR70, HAQ, adverse events.
Ren 2017	82	Active RA	IGU+MTX vs. MTX	26 weeks	Duration of morning stiffness, adverse events.
Wang 2017	120	Active RA	IGU+MTX vs. MTX	68 weeks	DAS28-ESR, adverse events.
Bai 2015	100	Active RA	IGU+MTX vs. MTX	24 weeks	ACR20, ACR50, adverse events.
Xie 2018	120	Refractory RA	IGU+MTX vs. MTX	17 weeks	DAS28-ESR, adverse events.
Wang 2016	87	Refractory RA	IGU+MTX vs. MTX	24 weeks	DAS28, adverse events.
Meng 2016	60	Refractory RA	IGU+MTX vs. MTX	16 weeks	DAS28-ESR, adverse events.
Chen 2018	120	Active RA	IGU+MTX vs. MTX	24 weeks	Duration of morning stiffness, adverse events.
Xu 2017	83	Active RA	IGU+MTX vs. MTX	52 weeks	DAS28, adverse events.
Xiong 2020	102	Active RA	IGU+MTX vs. MTX	24 weeks	Duration of morning stiffness, adverse events.
Lu 2009	326	Active RA	IGU vs. MTX	24 weeks	ACR20, ACR50, ACR70, duration of morning stiffness, HAQ, adverse events.
Yang 2017	60	Active RA	IGU vs. MTX	12 weeks	DAS28-ESR, duration of morning stiffness.
Hu 2014	40	Active RA	IGU vs. MTX	24 weeks	ACR20, DAS28-ESR, adverse events.
Dai 2019	108	Active RA	IGU+Leflunomide vs. Leflunomide	12 weeks	DAS28-3, duration of morning stiffness, adverse events.
Li 2018	60	Refractory RA	IGU+ Etanercept vs. Etanercept	12 weeks	DAS28-ESR, adverse events.

Back to article page

ISSN: 1749-799X

Contact us

Submission enquiries: journalsubmissions@springernature.com